Any BP interested in Peregrine would have analyzed and tested Bavituximab extensively in their own labs. To think otherwise would be short sighted. A PI clinical trial would confirm their findings and a 1st look in result could provide further validation in a late stage trial. The momentum is changing. If you hear about and read about it, you can connect the dots and see it. Success does not appear to be a long way off IMO.
Market Data 
Markets 
AI
